3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
14
Hirsutism
2
Thrombocytosis
1
Prostate Adenocarcinoma
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Non-Muscle Invasive Bladder Urothelial Carcinoma
1
Non Castrate Metastatic Prostate Cancer
1
Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lower Urinary Tract Symptoms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Glioma
1
Glioblastoma
1
Breast Neoplasms
1
Blast Crisis
1
Interventions
enzalutamide
2
gallium 68 PSMA-11
1
entinostat
1
bicalutamide
1
Radiosurgery
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Prostate Adenocarcinoma
×
bicalutamide
×
Clear all
NCT04943536
2026-02-27
BiolenRT
Alessa Therapeutics Inc.
Phase 1
Active not recruiting
20 enrolled